Selenoprotein P regulation by the glucocorticoid receptor.
Maintenance of the antioxidant activity of selenoproteins is one potential mechanism of the beneficial health effects of selenium. Selenoprotein P is the primary selenium distribution protein of the body as well as the major selenium containing protein in serum. The transcriptional regulation of selenoprotein P is of interest since the extrahepatic expression of this gene has demonstrated differentiation-dependent expression in development as well as under different disease states. SEPP1 displays patterned expression in numerous tissues during development and the loss of SEPP1 expression has been observed in malignancy. In addition, factors that influence inflammatory processes like cytokines and their regulators have been implicated in selenoprotein P transcriptional control. Herein, we identify a retinoid responsive element and describe a mechanism where the glucocorticoid receptor negatively regulates expression of selenoprotein P. Luciferase reporter assays and quantitative PCR were used to measure selenoprotein P transcription in engineered HEK-293 cells. When stimulated with ecdysone analogs, selenoprotein P expression was increased with the use of a fusion transcription factor that contains the glucocorticoid receptor DNA binding domain, an ecdysone ligand-binding domain, and a strong transactivation domain as well as the retinoid X receptor. The native glucocorticoid receptor inhibited selenoprotein P transactivation, and selenoprotein P was further attenuated in the presence of dexamethasone. Our results may provide insight into a potential mechanism by which selenium is redistributed during development, differentiation or under conditions of critical illness, where glucocorticoid levels are typically increased.
Rock
Colleen
C
Department of Pharmacology and Toxicology, University of Utah, L.S. Skagg's Pharmacy, Rm. 201, 30 S 2000 East, Salt Lake City, UT 84112, USA.
Moos
Philip J
PJ
D001483:Base Sequence; D003001:Cloning, Molecular; D003907:Dexamethasone / Q000494:pharmacology; D004440:Ecdysone / Q000031:analogs & derivatives / Q000494:pharmacology; D017930:Genes, Reporter; D057809:HEK293 Cells; D006801:Humans; D008156:Luciferases / Q000235:genetics / Q000378:metabolism; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D016133:Polymerase Chain Reaction; D017434:Protein Structure, Tertiary; D011965:Receptors, Glucocorticoid / Q000235:genetics / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism*; D020218:Response Elements / Q000187:drug effects; D047488:Retinoid X Receptors / Q000235:genetics / Q000378:metabolism*; D012643:Selenium / Q000378:metabolism; D051149:Selenoprotein P / Q000037:antagonists & inhibitors / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism*; D015533:Transcriptional Activation / Q000187:drug effects
D011965:Receptors, Glucocorticoid; D011993:Recombinant Fusion Proteins; D047488:Retinoid X Receptors; D051149:Selenoprotein P; D014157:Transcription Factors; D004440:Ecdysone; D003907:Dexamethasone; D008156:Luciferases; D012643:Selenium